COSELA^® received upgraded evidence-based medicine designation in the CSCO Guidelines for Small Cell Lung Cancer

点击量：278

On April 28, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharm...

Expanded Access Policy

点击量：398

Simcere pharma is a pharmaceutical company driven by innovative R&D, its mission is Providing To...

Simcere Zaiming will present six innovative researches at the 2024 AACR

点击量：1182

March 25 2024. Simcere Zaiming, the oncology subsidiary of Simcere Pharmaceutical Group Ltd, will pr...

Simcere Zaiming announces global FIH dosing of USP1 inhibitor in clinical trial

点击量：1007

On March 19, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharm...

Phase III Clinical Study of Daridorexant Achieved the Full Patient Enrollment in China

点击量：879

Phase III Clinical Study of Daridorexant Achieved the Full Patient Enrollment in ChinaOn March 15, 2...

New Drug Application Of Suvemcitug For Injection Has Been Accepted By the China National Medical Products Administration

点击量：875

On March 15, 2024, Simcere Zaiming Pharmaceutical Co. Ltd. (“Simcere Zaiming”), an innovative oncolo...